BlackRock Group’s PTC Therapeutics PTCT Stock Holding History

BlackRock Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.47M	Sell	134,470 -63,866	-32%	-$670K	﹤0.01%	1945
2016 Q3	$2.78M	Sell	198,336 -3,947	-2%	-$32.1K	﹤0.01%	1414
2016 Q2	$1.42M	Sell	202,283 -11,485	-5%	-$84.2K	﹤0.01%	1762
2016 Q1	$1.38M	Buy	213,768 +194,685	+1,020%	+$3.38M	﹤0.01%	1752
2015 Q4	$618K	Sell	19,083 -89,418	-82%	-$2.63M	﹤0.01%	2110
2015 Q3	$2.9M	Buy	108,501 +9,311	+9%	+$398K	﹤0.01%	1305
2015 Q2	$4.78M	Buy	99,190 +91,563	+1,201%	+$5.34M	﹤0.01%	1156
2015 Q1	$464K	Buy	7,627 +2,751	+56%	+$168K	﹤0.01%	2233
2014 Q4	$253K	Buy	4,876 +2,779	+133%	+$122K	﹤0.01%	2448
2014 Q3	$92K	Buy	2,097 +464	+28%	+$14.5K	﹤0.01%	2601
2014 Q2	$43K	Sell	1,633 -29,538	-95%	-$632K	﹤0.01%	2713
2014 Q1	$815K	Sell	31,171 -6,929	-18%	-$186K	﹤0.01%	2074
2013 Q4	$647K	Hold	38,100	–	–	﹤0.01%	2142
2013 Q3	$818K	Buy	+38,100	New	+$662K	﹤0.01%	2019

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

BlackRock Group's PTCT Position: Q4 2016 in Review

BlackRock Group reduced its PTC Therapeutics (PTCT) stake by 32% in Q4 2016, selling an estimated $670K and leaving 134,470 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

BlackRock Group first reported a position in PTCT in Q3 2013 and has held it in 14 quarters since. The position peaked at $4.78M in Q2 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

BlackRock Group held 134,470 shares of PTC Therapeutics worth $1.47M as of Q4 2016.
BlackRock Group sold 63,866 PTC Therapeutics shares in Q4 2016, an estimated $670K.
PTC Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1945 holding.
BlackRock Group first reported a position in PTC Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Group's PTC Therapeutics position peaked at $4.78M in Q2 2015.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.